Press Releases

Aug 04, 2021 8:30am EDT

Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment

Jul 29, 2021 7:05am EDT

Lexaria's DehydraTECH-CBD Lowers Blood Pressure

Jul 28, 2021 7:05am EDT

DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores

Jul 27, 2021 7:15am EDT

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Jul 26, 2021 2:40pm EDT

Lexaria Receives US$3,817,643 From Warrant Exercises

Jul 22, 2021 7:05am EDT

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

Jul 21, 2021 7:05am EDT

Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Jul 15, 2021 7:05am EDT

Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council

Jul 13, 2021 7:05am EDT

Lexaria Receives Patent Protection in Japan

Jul 05, 2021 8:00am EDT

Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets